MBOT241220P2500
- 0.00
- 0.000.00%
Microbot Medical Newsroom
Microbot Medical Stockholders Approve Key Proposals in 2024
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System
Microbot Medical CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 With Additional Growth Expected
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Microbot Medical | 10-Q: Q3 2024 Earnings Report
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
Express News | Microbot Medical Inc - Clinical Trial Results to Be Presented at Medical Conference in Early 2025
Express News | Microbot Medical Inc - 80% of Patients Completed Follow-up, Trial to Finish Ahead of Schedule
Microbot Medical Accelerates Patient Enrollment of Its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Express News | Microbot Medical Inc - to File 510(K) Submission With FDA by Year-End
Express News | Microbot Medical Announces the Successful Enrollment of 50% of the Patients in Its Pivotal Human Clinical Trial for the Liberty Endovascular Robotic Surgical System
Microbot Medical Shares Investor Presentation Update
Microbot Medical Advances Liberty Robotic System Telesurgery Innovation
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Express News | Microbot Medical Signs Phase 2 Collaboration Agreement With Corewell Health to Advance Remote Telesurgery Using the Liberty® Endovascular Robotic System
Microbot Medical Signs Phase 2 Collaboration Agreement With Corewell Health to Advance Remote Telesurgery Using the LIBERTY Endovascular Robotic System
Microbot Medical (MBOT) Gets Quality Certification for Its System
Microbot Medical | 10-Q: Q2 2024 Earnings Report